Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.3
4.1
Journals
Metabolites
Special Issues
Unravel Metabolism and Resistance Mechanisms in Glioblastoma
share announcement

Unravel Metabolism and Resistance Mechanisms in Glioblastoma

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Cell Metabolism".

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 5992

Special Issue Editors

Dr. Ana Luísa De Sousa-Coelho

E-Mail Website
Guest Editor
1. Algarve Biomedical Center Research Institute, ABC-RI, 8005-139 Faro, Portugal
2. Escola Superior de Saúde (ESSUAlg), Campus de Gambelas, Universidade do Algarve, 8005-139 Faro, Portugal
Interests: metabolism; cancer; metabolic reprogramming; Tribbles; drug repurposing; therapy resistance; cell signaling
Special Issues, Collections and Topics in MDPI journals
Dr. Bibiana I. Ferreira

E-Mail Website
Guest Editor
1. Faculdade de Medicina e Ciências Biomédicas (FMCB), Campus de Gambelas, Universidade do Algarve, 8005-139 Faro, Portugal
2. Algarve Biomedical Center Research Institute, ABC-RI, 8005-139 Faro, Portugal
Interests: cancer signaling; drug resistance; genomic alterations; copy number variations
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Glioblastomas are highly aggressive brain tumors, among the most deadly and incurable types of human cancer, which are greatly resistant to the standard treatments that are currently available. Cancer cells can metabolically adapt to changes in oxygen or nutrients in the microenvironment, making the dysregulation of cellular metabolism a hallmark of cancer, and a critical event in therapy resistance. Once identified, cellular metabolic susceptibilities could be exploited as novel therapeutic strategies. Drug repurposing is a very attractive alternative to the long pathway involved in new drugs development and approval, contributing to new targeted and successful personalized therapeutic approaches. Therefore, understanding the fundamental molecular mechanisms by which a metabolic shift may modulate cancer development is paramount, contributing to the development of novel therapeutic approaches and alternative targets.

In this Special Issue of Metabolites, we invite authors to submit contributions that provide novel findings in the field of glioblastoma. We plan to cover the latest advances in research on the basic mechanisms by which cellular metabolic reprogramming modulates cancer development and its role in the mechanisms of drug resistance, as well as the potential of repurposing drugs for glioblastoma-combined therapies. We welcome findings from basic research in both preclinical or clinical fields. Reviews that comprehensively highlight new findings in these field are also welcome.

We look forward to receiving your contributions.

Dr. Ana Luísa De Sousa-Coelho
Dr. Bibiana I. Ferreira
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • glioblastoma
  • glioma
  • therapeutic resistance
  • resistance mechanisms
  • metabolic rewiring
  • therapeutic opportunities
  • cancer metabolism
  • tumor microenvironment
  • metabolomics
  • metabonomics
  • drugs repurposing

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

26 pages, 1548 KiB  
Review
Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview
by Ahmed Ismail Eatmann, Esraa Hamouda, Heba Hamouda, Hossam Khaled Farouk, Afnan W. M. Jobran, Abdallah A. Omar, Alyaa Khaled Madeeh, Nada Mostafa Al-dardery, Salma Elnoamany, Eman Gamal Abd-Elnasser, Abdullah Muhammed Koraiem, Alhassan Ali Ahmed, Mohamed Abouzid and Marta Karaźniewicz-Łada
Metabolites 2023, 13(4), 543; https://doi.org/10.3390/metabo13040543 - 11 Apr 2023
Cited by 2 | Viewed by 3146
Abstract
Glioblastoma is the most common malignant primary brain tumor in adults. Thalidomide is a vascular endothelial growth factor inhibitor that demonstrates antiangiogenic activity, and may provide additive or synergistic anti-tumor effects when co-administered with other antiangiogenic medications. This study is a comprehensive review [...] Read more.
Glioblastoma is the most common malignant primary brain tumor in adults. Thalidomide is a vascular endothelial growth factor inhibitor that demonstrates antiangiogenic activity, and may provide additive or synergistic anti-tumor effects when co-administered with other antiangiogenic medications. This study is a comprehensive review that highlights the potential benefits of using thalidomide, in combination with other medications, to treat glioblastoma and its associated inflammatory conditions. Additionally, the review examines the mechanism of action of thalidomide in different types of tumors, which may be beneficial in treating glioblastoma. To our knowledge, a similar study has not been conducted. We found that thalidomide, when used in combination with other medications, has been shown to produce better outcomes in several conditions or symptoms, such as myelodysplastic syndromes, multiple myeloma, Crohn’s disease, colorectal cancer, renal failure carcinoma, breast cancer, glioblastoma, and hepatocellular carcinoma. However, challenges may persist for newly diagnosed or previously treated patients, with moderate side effects being reported, particularly with the various mechanisms of action observed for thalidomide. Therefore, thalidomide, used alone, may not receive significant attention for use in treating glioblastoma in the future. Conducting further research by replicating current studies that show improved outcomes when thalidomide is combined with other medications, using larger sample sizes, different demographic groups and ethnicities, and implementing enhanced therapeutic protocol management, may benefit these patients. A meta-analysis of the combinations of thalidomide with other medications in treating glioblastoma is also needed to investigate its potential benefits further. Full article
(This article belongs to the Special Issue Unravel Metabolism and Resistance Mechanisms in Glioblastoma)
►▼ Show Figures

Graphical abstract

Other

Jump to: Review

29 pages, 2402 KiB  
Systematic Review
Lipid Alterations in Glioma: A Systematic Review
by Khairunnisa Abdul Rashid, Kamariah Ibrahim, Jeannie Hsiu Ding Wong and Norlisah Mohd Ramli
Metabolites 2022, 12(12), 1280; https://doi.org/10.3390/metabo12121280 - 16 Dec 2022
Cited by 5 | Viewed by 1990
Abstract
Gliomas are highly lethal tumours characterised by heterogeneous molecular features, producing various metabolic phenotypes leading to therapeutic resistance. Lipid metabolism reprogramming is predominant and has contributed to the metabolic plasticity in glioma. This systematic review aims to discover lipids alteration and their biological [...] Read more.
Gliomas are highly lethal tumours characterised by heterogeneous molecular features, producing various metabolic phenotypes leading to therapeutic resistance. Lipid metabolism reprogramming is predominant and has contributed to the metabolic plasticity in glioma. This systematic review aims to discover lipids alteration and their biological roles in glioma and the identification of potential lipids biomarker. This systematic review was conducted using the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. Extensive research articles search for the last 10 years, from 2011 to 2021, were conducted using four electronic databases, including PubMed, Web of Science, CINAHL and ScienceDirect. A total of 158 research articles were included in this study. All studies reported significant lipid alteration between glioma and control groups, impacting glioma cell growth, proliferation, drug resistance, patients’ survival and metastasis. Different lipids demonstrated different biological roles, either beneficial or detrimental effects on glioma. Notably, prostaglandin (PGE2), triacylglycerol (TG), phosphatidylcholine (PC), and sphingosine-1-phosphate play significant roles in glioma development. Conversely, the most prominent anti-carcinogenic lipids include docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and vitamin D3 have been reported to have detrimental effects on glioma cells. Furthermore, high lipid signals were detected at 0.9 and 1.3 ppm in high-grade glioma relative to low-grade glioma. This evidence shows that lipid metabolisms were significantly dysregulated in glioma. Concurrent with this knowledge, the discovery of specific lipid classes altered in glioma will accelerate the development of potential lipid biomarkers and enhance future glioma therapeutics. Full article
(This article belongs to the Special Issue Unravel Metabolism and Resistance Mechanisms in Glioblastoma)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop